Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gassur.2025.102179 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anemia and iron deficiency in post-kidney transplantation: an unsolved challenge.
Clin Kidney J
September 2025
Prof Department of Advanced Medical and Surgical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Anemia and iron deficiency (ID) are common and significant complications in kidney transplant recipients (KTRs) that can affect their health-related quality of life (HRQoL) and outcomes. Current anemia guidelines equate the post-transplant situation with the anemia associated with chronic kidney disease (CKD) in non-transplanted persons, not acknowledging relevant differences ranging from pathophysiology to clinical manifestation. Nephrologists caring for these patients tend to pay less attention to post-transplant anemia (PTA) and ID than in non-transplanted persons with CKD.
View Article and Find Full Text PDFA Sinonasal Paranasal Mesenchymal Tumor Associated With Tumor-Induced Osteomalacia: A Case Report and Literature Review.
Ear Nose Throat J
September 2025
International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Introduction: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome that is characterized by hypophosphatemia resulting from the leakage of renal phosphate. Due to its diverse and nonspecific clinical manifestations, the diagnosis is often delayed.
Case Report: We present the rare case of a 33-year-old man with TIO who was presented with chronic bilateral hip joint pain and was initially misdiagnosed with osteonecrosis of the femoral head.
Diagnostic Journey in the Recognition of Oncogenic Osteomalacia.
JCEM Case Rep
October 2025
Department of Neurological Surgery, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, PA.
A 73-year-old woman with a remote history of successfully treated primary hyperparathyroidism was referred to our office because of multiple skeletal fractures and proximal muscle weakness. Prior laboratory evaluation demonstrated hypocalcemia, vitamin D deficiency, elevated PTH, and elevated alkaline phosphatase. Updated evaluation in our clinic additionally showed hypophosphatemia prompting measurement of serum fibroblast growth factor 23 (FGF23).
View Article and Find Full Text PDFFailure of femoral internal fixation device secondary to phosphaturic mesenchymal tumor: a case report and literature review.
BMC Musculoskelet Disord
September 2025
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Background: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by mesenchymal tumors that secrete fibroblast growth factor 23 (FGF23). Phosphaturic mesenchymal tumor (PMT) is a novel histopathologic entity that has been identified as a separate cause of TIO. Clinically, PMT is typically diagnosed late due to its rarity.
View Article and Find Full Text PDFA Comparative Nonrandomised Observational Study of Different Modalities of Renal Replacement Therapy (Continuous Renal Replacement Therapy vs. Sustained Low Efficiency Dialysis) With Acute Kidney Injury in an Intensive Care Unit Setup: A Pilot Study.
Cureus
July 2025
Nephrology, Jaslok Hospital and Research Center, Mumbai, IND.
Background: This study investigated the comparable efficacy of sustained low-efficiency dialysis (SLED) over continuous renal replacement therapy (CRRT) in maintaining hemodynamic stability in critically ill patients with acute kidney injury (AKI) in an intensive care unit (ICU).
Methods: A single-centre, prospective observational study was conducted at Jaslok Hospital and Research Centre, Mumbai, involving 67 patients requiring RRT in the ICU. Thirty-five patients were included in the CRRT (Baxter Prismaflex System, USA) cohort, and 32 patients were included in the SLED (Fresenius 4008S, Fresenius Medical Care, Bad Hamburg, Germany) cohort.